Extending EPCAT III's Findings Across Acute Interventions: A Translational Symmetry Argument

 

A recent trial (EPCAT III), led by Dr. Sudeep Shivakumar and colleagues, found aspirin alone noninferior to rivaroxaban-then-aspirin for preventing venous thromboembolism after hip or knee arthroplasty, with no meaningful bleeding difference. This raises a natural question: could a lighter strategy work just as well after other acute, self-resolving surgical or trauma events? Our book, Symmetry in Health and Illness, doesn't address this trial directly, but its application of translational symmetry to medicine offers a way to reason about extending the result.

Structure and Function Together

We apply translational symmetry to medicine as a pattern where a structure repeats across the body, and the function tied to that structure repeats along with it. This is already how the concept works in our own examples: nephrons repeat structurally and each performs the same filtration function; sarcomeres repeat structurally and each contributes the same contraction function. Structure and function repeat together, not one without the other. 

The Principle's Reach Across Therapeutic Domains

This functional version of the principle is visible across nearly every therapeutic domain, well beyond the book's own anatomical examples. Anti-inflammatory medications treat the same underlying inflammatory function whether it manifests as rheumatoid arthritis, inflammatory bowel disease, or psoriasis. Antianginal drugs relieve the same underlying ischemic function whether pain presents in the chest, the jaw, or the left arm. In each case, a therapy validated against one manifestation of a functional mechanism transfers to other manifestations of that same mechanism — because the function repeats, even where the anatomy or trigger differs. Coagulation belongs to this same category: a physiological function that activates and resolves the same way regardless of which tissue or injury triggers it.

Why Aspirin's Dual Action Matters Here

This matters especially for aspirin, which isn't purely an antiplatelet agent — it is also anti-inflammatory. Tissue injury from surgery, including arthroplasty, triggers both a hypercoagulable state and a local inflammatory response, and these two processes are mechanistically linked. Aspirin's noninferiority in the Shivakumar-led EPCAT III trial may reflect this combined action, addressing both the platelet activation and the inflammatory component of post-surgical tissue injury simultaneously, rather than antiplatelet activity alone.

Applying the Logic to Other Acute Events

Arthroplasty is one manifestation of a broader repeating pattern: acute tissue injury producing combined inflammation and transient hypercoagulability, both resolving as healing progresses. Other major surgeries and acute trauma share this same combined function. If aspirin's effectiveness in arthroplasty comes from addressing both processes together, translational symmetry suggests the same combined benefit could extend to other acute events built on this same injury-inflammation-coagulation pattern.

Why Clinical Testing Remains Necessary

This reasoning explains why the hypothesis is worth pursuing, not why it is already proven. Acute events differ in the degree of tissue trauma, inflammatory response, and clotting activation, so the shared pattern must be confirmed empirically for each new context, just as EPCAT III itself was needed to establish the result for arthroplasty specifically.

The Necessary Caveat

This reasoning only holds where the new event shares the same underlying pattern: acute, self-limited tissue injury driving both inflammation and coagulation together. A condition built on a different mechanism — permanent structural risk, as in atrial fibrillation or a mechanical heart valve — doesn't share this pattern and wouldn't be expected to respond the same way. Translational symmetry justifies testing the arthroplasty finding in genuinely similar acute events; it doesn't replace the need for verification in each one.

You can learn more by reading our e-book 

Mykola Iabluchanskyi together with Andriy Yabluchanskiy